Jurata provides thermostable formulation technologies that keep biologic APIs active at ambient or elevated temperatures, eliminating the need for cold‑chain logistics. Their platform supports both liquid and thin‑film formats for a range of delivery routes, including injectable and needle‑free options, and is compatible with vaccines, gene therapies, antibodies, proteins, and peptides. This enables pharmaceutical and biotech developers to simplify manufacturing, reduce shipping costs, and expand product access worldwide.
Funding
$4.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JJFounders
Product
Problem
Biologics, vaccines, and advanced therapeutics often require strict cold-chain logistics and specialized handling, which increase manufacturing complexity, shipping costs, and limit access in remote or resource‑limited settings.
Solution
Jurata provides thermostable formulation technologies that preserve the activity of a wide range of biologic APIs at ambient or elevated temperatures. Their platform offers both liquid and thin‑film presentations, enabling standard injectable delivery as well as needle‑free routes such as oral, sublingual, buccal, and intranasal administration. By stabilizing the three‑dimensional structure of the active ingredient without the need for lyophilization, the formulations simplify manufacturing, reduce or eliminate cold‑chain requirements, and lower shipping and storage footprints. The technology is compatible with vaccines, gene therapies, antibodies, proteins, peptides, and other biologics, allowing developers to integrate stability enhancements into existing development programs and expand product accessibility.
Target Audience
Jurata’s primary customers are pharmaceutical and biotech companies developing vaccines, gene therapies, and other biologic products that require stable, temperature‑tolerant formulations for global distribution.
Features
- Liquid formulation that can be filled into vials, autoinjector pens, or other standard devices for intravenous, intramuscular, subcutaneous, and oral delivery
- Thin‑film formulation suitable for sublingual, buccal, oral, or reconstitution into liquid, offering lightweight, low‑volume packaging
- Proven stability of diverse modalities (live attenuated, inactivated, recombinant, subunit vaccines, VLPs, toxoids, viral/bacterial platforms, antibodies, plasmid DNA, peptides, proteins) at ambient and elevated temperatures
- Elimination of cold‑chain logistics, enabling shipment to pharmacies, homes, or remote locations without temperature control
- Support for needle‑free administration routes, reducing reliance on specialized healthcare personnel and facilitating self‑administration
- Compatibility with existing manufacturing processes, avoiding the need for API lyophilization or major formulation changes